MUC4 Gene Polymorphism Detection for Diffuse Alveolar Damage Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively determine the risk of diffuse alveolar damage, a serious side effect of anticancer drug therapy, particularly in Japanese patients, due to lack of identified gene polymorphisms associated with the condition, which complicates early differentiation from normal pneumonia and poses a high case fatality rate.
Innovation Solution
A method involving the detection of specific MUC4 gene polymorphisms, such as rs6805660 and rs62282486, to assess the risk of diffuse alveolar damage, allowing for the identification of patients at risk before or during anticancer drug administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anticancer drugs are administered to treat cancer, then cancer treatment efficacy is improved, but the risk of diffuse alveolar damage increases
Solution Approach 1:
The patent applies preliminary action by detecting MUC4 gene polymorphisms before administering anticancer drugs to identify patients at high risk of diffuse alveolar damage. This allows preventive measures to be taken before the harmful effect occurs, while still enabling effective cancer treatment for those without the risk polymorphism.
Solution Approach 2:
The patent applies local quality by identifying specific genetic characteristics (MUC4 polymorphisms) in particular patient populations (Japanese patients) who are susceptible to diffuse alveolar damage. This enables targeted risk assessment and personalized treatment decisions for specific subgroups rather than applying uniform restrictions to all patients.
2Measurement precision
If MUC4 gene polymorphism detection is performed to assess diffuse alveolar damage risk, then risk determination accuracy is improved, but diagnostic complexity increases
Solution Approach 1:
The patent applies taking out by extracting and focusing on specific MUC4 gene polymorphism sites that are directly associated with diffuse alveolar damage risk. Rather than analyzing the entire genome or multiple unrelated markers, the invention isolates and detects only the critical polymorphic sites, simplifying the diagnostic process while maintaining high accuracy.
3Object-affected harmful factors
If gene polymorphism detection methods are developed to identify diffuse alveolar damage risk, then patient safety is improved, but the difficulty of detecting and measuring increases
Solution Approach 1:
The patent applies mechanics substitution by replacing complex mechanical or invasive diagnostic methods with molecular biological detection techniques. The use of PCR and other molecular methods to detect MUC4 polymorphisms is less invasive and more specific than traditional imaging or functional tests, reducing detection difficulty while improving patient safety assessment.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The purpose of the present invention is to provide an evaluation method and evaluation kit for evaluating the risk of onset of diffuse alveolar damage due to such factors as anticancer drug administration. The purpose of the present invention is also to provide a method for evaluating the risk of onset of side effects in anticancer drug treatment. An evaluation method and evaluation kit for evaluating the risk of onset of diffuse alveolar damage, including detecting gene polymorphism present in the MUC4 gene. A method for evaluating the risk of onset of side effects in anticancer drug treatment, including detecting gene polymorphism present in the MUC4 gene of a patient scheduled for anticancer drug administration.